Discover

RVTY
Revvity, Inc.
110.52
1 x 106.45
1 x 110.36
bid
ask
+
4.08
3.83%
04:00 PM
Ytd14.23%
1y21.83%
103.50
day range
112.29
81.22
52 week range
118.30
Open103.50Prev Close106.44Low103.50High112.29Mkt Cap12.33B
Vol1.34MAvg Vol1.49MEPS5.12P/E21.59Forward P/E21.01
Beta1.09Short Ratio4.94Inst. Own106.38%Dividend0.28Div Yield0.25
Ex Div Date07-17Earning08-0450-d Avg103.68200-d Avg98.121yr Est117.13
Earning
DateForEstimateReportedSurprisesurprise %
2026-08-042026-071.23N/AN/AN/A
2026-05-052026-041.021.060.043.92%
2026-02-022025-121.571.70.138.28%
2025-10-272025-091.141.180.043.51%
2025-07-282025-061.141.180.043.51%
2025-04-282025-030.961.010.055.21%
Upgrade / Downgrade
DateFirmActionFromTo
2026-07-06Evercore ISI GroupUpgradeOutperformOutperform
2026-05-07BarclaysUpgradeEqual-WeightEqual-Weight
2026-05-06JP MorganUpgradeNeutralNeutral
2026-05-06TD CowenUpgradeBuyBuy
2026-05-06StifelUpgradeHoldHold
2026-05-04BairdUpgradeOutperformOutperform
Profile
Revvity, Inc. provides health sciences solutions, technologies, and services. The company offers instruments, reagents, software, subscriptions, detection and imaging technologies, extended warranties, training and services; and instruments, reagents, assay platforms and software products for early detection of common and rare conditions, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. The company also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, chemagic, Chitas, CNGnome, DELFIA, DELFIA Xpress, EONIS, EUROArray , EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, GSP, Haoyuan, IDS Immunodiagnosticsystems, IDS-i10, IDS-i10T, IDS-i20, IDS-iSYS, iLab, iQ, LifeCycle, LimsLink, Migele, NeoBase, NeoLSD, NEXTFLEX, Panthera Puncher, PreNAT II, Prime, RONIA, SimplicityChrom, Specimen Gate, Superflex, Symbio, T-SPOT, Vanadis, ViaCord, VICTOR2, and WholePanel brand names, as well as under the Accell, AlphaLISA, AlphaPlex, AlphaScreen, Alpha SureFire, AssayMate, BIOCHIPs, BioLegend, Bioo Scientific, BioQule, Brilliant Violet, Ce3D, CellCarrier, Cellaca, Celigo, Cellometer, cell::explorer, Cell-Vive, Chalice, ChemDraw, CHOSOURCE, Dharmacon, and DharmaFECT brand names. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
Insider Holder
DateNameRelationQuantityDescription
2026-05-06BARRETT PETERDirector28.29KStock Award(Grant)
2026-05-06CHAPIN SAMUEL R.Director22.68KStock Award(Grant)
2026-02-04GOLDBERG JOEL SGeneral Counsel106.96KSale
2026-02-03KRAKOWIAK MAXWELLChief Financial Officer18.77KStock Award(Grant)
2026-05-06MICHAS ALEXANDROS PDirector71.54KStock Award(Grant)
2025-08-26MICHAS ALEXIS PDirector0.00Sale
Institution Ownership
Report DateOrganizationPositionValuePercentage
2026-03-30T. Rowe Price Investment Management,Inc.22.20M0.0019.90%
2025-12-30Vanguard Group Inc13.16M0.0011.80%
2026-03-30T. Rowe Price Associates, Inc.10.09M0.009.04%
2026-03-30EdgePoint Investment8.80M0.007.89%
2026-03-30HHG PLC8.35M0.007.48%
2026-03-30Vanguard Capital Management, LLC7.33M0.006.57%
Fund Ownership
Report DateOrganizationPositionValuePercentage
2026-06-29T. Rowe Price Capital Appreciation11.24M0.0010.07%
2026-04-29Janus Henderson Enterprise D5.75M0.005.15%
2026-03-30Janus Inst Mid Cap Growth CF5.62M0.005.04%
2026-03-30EdgePoint Global3.68M0.003.30%
2026-03-30EdgePoint Global Portfolio Series F3.68M0.003.30%
2026-06-29Vanguard Total Stock Mkt Idx Inv3.55M0.003.18%
Dividend
DividendDate
0.072026-07-17
0.072026-04-17
0.072026-01-16
0.072025-10-17
0.072025-07-18
0.072025-04-17